News & Updates

Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.

Hematochezia and abdominal pain are strong indicators of colorectal cancer (CRC), with the likelihood of CRC increasing by up to six- and 54-fold in the presence of such symptoms, according to a meta-analysis.

First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.

Women on testosterone therapy (TTh) show a lower risk of major adverse cardiac events (MACE) than matched controls, while postmenopausal women have a comparable MACE risk and a similar or significantly reduced risk of breast cancer on age-based subanalysis, reports a study.

Eating legumes may help avert the development of colorectal cancer, according to a study that has found an inverse association between legume consumption and colorectal cancer risk.

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.

A history of breast cancer (BC) appears protective against mortality in patients with thyroid cancer (TC), suggests a study. This benefit is most pronounced with papillary TC (PTC) in patients who had TC first before BC (TC-1st patients), especially in those with a history of ER-positive BC.